Search details
1.
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
N Engl J Med
; 389(6): 491-503, 2023 Aug 10.
Article
in English
| MEDLINE | ID: mdl-37272513
2.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
N Engl J Med
; 389(20): 1839-1850, 2023 Nov 16.
Article
in English
| MEDLINE | ID: mdl-37870973
3.
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
Lancet
; 401(10378): 733-746, 2023 03 04.
Article
in English
| MEDLINE | ID: mdl-36764316
4.
CT-Guided Core-Needle Biopsy of Pulmonary Lesions Associated With Cystic Airspaces: A Case-Control Study.
AJR Am J Roentgenol
; 2024 May 08.
Article
in English
| MEDLINE | ID: mdl-38717239
5.
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI.
Future Oncol
; 20(15): 969-980, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38095056
6.
Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy.
Cancer
; 129(11): 1662-1671, 2023 06 01.
Article
in English
| MEDLINE | ID: mdl-36905392
7.
RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
Oncologist
; 28(5): 402-413, 2023 05 08.
Article
in English
| MEDLINE | ID: mdl-36821595
8.
Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies.
Int J Mol Sci
; 24(10)2023 May 17.
Article
in English
| MEDLINE | ID: mdl-37240229
9.
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
Lancet Oncol
; 23(4): 540-552, 2022 04.
Article
in English
| MEDLINE | ID: mdl-35358455
10.
Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling.
BMC Cancer
; 22(1): 1212, 2022 Nov 24.
Article
in English
| MEDLINE | ID: mdl-36434615
11.
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Curr Treat Options Oncol
; 23(12): 1699-1720, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36394791
12.
Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial.
Future Oncol
; 18(16): 1907-1915, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35285277
13.
Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study.
Pathologica
; 114(4): 278-287, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-36083243
14.
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 379(21): 2040-2051, 2018 11 22.
Article
in English
| MEDLINE | ID: mdl-30280635
15.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med
; 378(22): 2078-2092, 2018 May 31.
Article
in English
| MEDLINE | ID: mdl-29658856
16.
Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?
Curr Oncol Rep
; 23(1): 10, 2021 01 02.
Article
in English
| MEDLINE | ID: mdl-33387080
17.
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.
Future Oncol
; 17(7): 763-773, 2021 Mar.
Article
in English
| MEDLINE | ID: mdl-33150799
18.
Wnt/IL-1ß/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.
Int J Cancer
; 146(1): 192-207, 2020 01 01.
Article
in English
| MEDLINE | ID: mdl-31107974
19.
An examination of two dichotomies: Women with lung cancer and living with lung cancer as a chronic disease.
Respirology
; 25 Suppl 2: 24-36, 2020 11.
Article
in English
| MEDLINE | ID: mdl-33124087
20.
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(12): 1655-1669, 2019 12.
Article
in English
| MEDLINE | ID: mdl-31591063